Fig. 6From: Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysisMeta-analysis estimated LRC comparing cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy. (a) subgroup of estimation of 2-yr LRC; (b) subgroup of estimation of 3-yr LRC. LRC, locoregional controlBack to article page